Fig. 5.
Fig. 5. Description of combined and single endpoints in HIT patients treated with lepirudin, or danapariod, or phenprocoumon, or other treatments. / Incidences of the combined and single endpoints of death, limb amputation, and new TEC at day 35 are given in percentages and corresponding 95% confidence intervals (CI) for lepirudin-treated patients (n = 113) and historical control patients (total, n = 75; danaparoid, n = 24; phenprocoumon, n = 21; others, n = 30).

Description of combined and single endpoints in HIT patients treated with lepirudin, or danapariod, or phenprocoumon, or other treatments.

Incidences of the combined and single endpoints of death, limb amputation, and new TEC at day 35 are given in percentages and corresponding 95% confidence intervals (CI) for lepirudin-treated patients (n = 113) and historical control patients (total, n = 75; danaparoid, n = 24; phenprocoumon, n = 21; others, n = 30).

Close Modal

or Create an Account

Close Modal
Close Modal